JP2013510885A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013510885A5 JP2013510885A5 JP2012539065A JP2012539065A JP2013510885A5 JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5 JP 2012539065 A JP2012539065 A JP 2012539065A JP 2012539065 A JP2012539065 A JP 2012539065A JP 2013510885 A5 JP2013510885 A5 JP 2013510885A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- composition
- compound
- nhch
- optical isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 21
- 230000003287 optical effect Effects 0.000 claims 10
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26130109P | 2009-11-13 | 2009-11-13 | |
| US61/261,301 | 2009-11-13 | ||
| US26247409P | 2009-11-18 | 2009-11-18 | |
| US61/262,474 | 2009-11-18 | ||
| PCT/US2010/056760 WO2011060392A1 (en) | 2009-11-13 | 2010-11-15 | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013235966A Division JP5982705B2 (ja) | 2009-11-13 | 2013-11-14 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
| JP2014229895A Division JP2015038145A (ja) | 2009-11-13 | 2014-11-12 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013510885A JP2013510885A (ja) | 2013-03-28 |
| JP2013510885A5 true JP2013510885A5 (cg-RX-API-DMAC7.html) | 2014-01-09 |
| JP5650233B2 JP5650233B2 (ja) | 2015-01-07 |
Family
ID=43992106
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539065A Active JP5650233B2 (ja) | 2009-11-13 | 2010-11-15 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
| JP2013235966A Active JP5982705B2 (ja) | 2009-11-13 | 2013-11-14 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
| JP2014229895A Pending JP2015038145A (ja) | 2009-11-13 | 2014-11-12 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013235966A Active JP5982705B2 (ja) | 2009-11-13 | 2013-11-14 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
| JP2014229895A Pending JP2015038145A (ja) | 2009-11-13 | 2014-11-12 | 選択的スフィンゴシン−１−リン酸受容体変調因子および不斉合成方法 |
Country Status (32)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY161854A (en) | 2009-11-13 | 2017-05-15 | Receptos Inc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| RS57070B1 (sr) | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
| CA2877097C (en) * | 2012-06-21 | 2018-08-07 | Eisai R&D Management Co., Ltd. | Novel indanesulfamide derivative |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| EP3062792A1 (en) * | 2013-11-01 | 2016-09-07 | Celgene International II Sarl | Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith |
| AU2016246398A1 (en) | 2015-04-06 | 2017-10-26 | Auspex Pharmaceuticals, Inc. | Deuterium-substituted oxadiazoles |
| EP3470400B1 (en) * | 2016-06-14 | 2025-04-02 | Receptos LLC | Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof |
| BR112019001153A2 (pt) * | 2016-07-22 | 2019-04-30 | Shijiazhuang Sagacity New Drug Development Co., Ltd. | agonista s1p1 e aplicação do mesmo |
| CN109563059A (zh) | 2016-08-19 | 2019-04-02 | 苏州科睿思制药有限公司 | 奥扎莫德的晶型及其制备方法 |
| US11117875B2 (en) | 2016-09-14 | 2021-09-14 | Hangzhou Solipharma Co., Ltd. | Crystalline forms, preparation methods and pharmaceutical compositions of ozanimod |
| WO2018050091A1 (zh) | 2016-09-14 | 2018-03-22 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| WO2018064356A1 (en) | 2016-09-29 | 2018-04-05 | Celgene International Ii Sarl | Compounds and methods for treating lupus |
| US10981900B2 (en) * | 2017-02-28 | 2021-04-20 | Medshine Discovery Inc. | Spiro compound and use thereof |
| US20200031784A1 (en) * | 2017-04-07 | 2020-01-30 | Solipharma Llc | Ozanimod addition salt crystal, preparation method, pharmaceutical composition, and uses |
| CN108727292A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 一种奥扎莫德及其中间体的制备方法 |
| CN108727291A (zh) * | 2017-04-21 | 2018-11-02 | 宁波爱诺医药科技有限公司 | 奥扎莫德及其中间体的制备方法 |
| US11207301B2 (en) | 2017-05-08 | 2021-12-28 | Receptos Llc | Sphingosine 1 phosphate receptor agonists for neuroprotection |
| EA201992421A1 (ru) * | 2017-05-22 | 2020-03-27 | Эгиш Дьёдьсердьяр Зрт. | Способ получения озанимода |
| CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| CN109280035B (zh) * | 2017-07-19 | 2023-06-09 | 广东东阳光药业有限公司 | 奥扎莫德的多晶型及其制备方法 |
| CN110944982A (zh) * | 2017-08-31 | 2020-03-31 | 苏州科睿思制药有限公司 | 奥扎莫德盐酸盐的晶型及其制备方法 |
| WO2019058290A1 (en) * | 2017-09-20 | 2019-03-28 | Suven Life Sciences Limited | IMPROVED PROCESS FOR THE PREPARATION OF AZANIMOD A-AMINO COMPOUND |
| WO2019094409A1 (en) | 2017-11-07 | 2019-05-16 | Teva Pharmaceuticals International Gmbh | Salts and solid state forms of ozanimod |
| CN107857760A (zh) * | 2017-11-21 | 2018-03-30 | 南京天翔医药科技有限公司 | 鞘氨醇‑1‑磷酸受体调节剂及其应用 |
| WO2019141245A1 (zh) * | 2018-01-18 | 2019-07-25 | 南京明德新药研发股份有限公司 | 一种三并环化合物的晶型、盐型及其制备方法 |
| KR20200132858A (ko) | 2018-03-20 | 2020-11-25 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 간질 치료제 |
| CN110615747A (zh) * | 2018-06-20 | 2019-12-27 | 广东东阳光药业有限公司 | 一种二氢茚中间体的制备方法 |
| WO2020005313A1 (en) | 2018-06-25 | 2020-01-02 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US20210340115A1 (en) | 2018-09-12 | 2021-11-04 | Pharmazell Gmbh | A PROCESS FOR THE PREPARATION OF OZANIMOD AND ITS INTERMEDIATE (S)-l-AMINO-2,3-DIHYDRO-1H-INDENE-4-CARBONITRILE |
| AR116479A1 (es) | 2018-09-25 | 2021-05-12 | Quim Sintetica S A | Intermediarios para la síntesis de ozanimod y procedimiento para la preparación del mencionado agonista del receptor de esfingosina-1-fosfato y de dichos intermediarios |
| MX2021006692A (es) | 2018-12-07 | 2021-07-07 | Synthon Bv | Proceso mejorado para preparar ozanimod. |
| EP3947363A4 (en) * | 2019-03-29 | 2023-01-04 | Receptos Llc | SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATORS |
| JP2022528001A (ja) * | 2019-03-29 | 2022-06-07 | レセプトス・リミテッド・ライアビリティ・カンパニー | スフィンゴシン１リン酸受容体調節因子 |
| KR20210150371A (ko) * | 2019-03-29 | 2021-12-10 | 리셉토스 엘엘씨 | 스핑고신 1 포스페이트 수용체 조절제 |
| EP3959204A4 (en) * | 2019-04-26 | 2022-12-28 | Receptos Llc | SPHINGOSINE-1-PHOSPHATE RECEPTOR MODULATOR |
| CN112062785B (zh) * | 2019-06-11 | 2023-06-27 | 广东东阳光药业有限公司 | 奥扎莫德及其中间体的制备方法 |
| EP3999495A1 (en) | 2019-07-16 | 2022-05-25 | Synthon B.V. | Improved process for preparing ozanimod |
| WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| JP2023509698A (ja) * | 2020-01-06 | 2023-03-09 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｓ１ｐ１受容体に関連した状態の処置方法 |
| EP4116294B1 (en) * | 2020-03-04 | 2025-09-03 | Helioeast Pharmaceutical Co., Ltd. | Benzo 2-azaspiro[4.4]nonane compound and use thereof |
| EP4116295A4 (en) * | 2020-03-04 | 2023-08-02 | Helioeast Pharmaceutical Co., Ltd. | TRICYCLIC COMPOUNDS AND THEIR USE |
| US11723895B2 (en) | 2020-03-17 | 2023-08-15 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of coronavirus infection |
| EP4126829A1 (en) * | 2020-03-27 | 2023-02-08 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| US12428386B2 (en) * | 2020-03-27 | 2025-09-30 | Receptos Llc | Sphingosine 1 phosphate receptor modulators |
| EP4126826A1 (en) | 2020-04-02 | 2023-02-08 | Synthon B.V. | Crystalline form of ozanimod hydrochloride |
| CN111620788B (zh) * | 2020-04-20 | 2022-09-30 | 广东莱佛士制药技术有限公司 | 一种制备(2s,3s)-3-氨基-二环[2.2.2]辛烷-2-甲酸酯的方法 |
| JP7738667B2 (ja) * | 2021-04-09 | 2025-09-12 | ヒーリオイースト ファーマシューティカル カンパニー リミテッド | オキサジアゾール置換スピロ環系化合物とその使用 |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
| WO2023152767A1 (en) | 2022-02-11 | 2023-08-17 | Mylan Laboratories Limited | Polymorphic forms of ozanimod hydrochloride |
| CN121194965A (zh) | 2023-05-31 | 2025-12-23 | 奎米卡新特缇卡股份有限公司 | 盐酸奥扎莫德的无定形形式和晶型 |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
| CN119462405B (zh) * | 2025-01-10 | 2025-05-27 | 天津阿尔塔科技有限公司 | 一种氘标记鞘氨醇类化合物和氘标记神经酰胺类化合物的制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
| FR2628103B1 (fr) | 1988-03-03 | 1991-06-14 | Roussel Uclaf | Nouveaux esters pyrethrinoides portant un noyau indanyle, leur procede de preparation et leur application comme pesticides |
| US5039802A (en) | 1990-04-18 | 1991-08-13 | Merck & Co., Inc. | Arylation process for preparation of chiral catalysts for ketone reduction |
| AU1886892A (en) | 1991-04-12 | 1992-11-17 | Schering Corporation | Bicyclic amides as inhibitors of acyl-coenzyme a: cholesterol acyl transferase |
| GB2290790A (en) | 1994-06-30 | 1996-01-10 | Merck & Co Inc | Asymmetric synthesis of 6-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes |
| NZ505599A (en) * | 1998-01-23 | 2003-06-30 | Sankyo Co | Morpholino alkyl substituted spiropiperidine derivatives useful as tachykinin receptor antagonists |
| AR035585A1 (es) † | 2000-09-15 | 2004-06-16 | Pharmacia Corp | Derivados del acido 2-amino-2-alquil-4-heptenoico, composicion farmaceutica y su uso en la fabricacion de medicamentos |
| US20040058894A1 (en) | 2002-01-18 | 2004-03-25 | Doherty George A. | Selective S1P1/Edg1 receptor agonists |
| CA2509218C (en) * | 2002-12-20 | 2010-09-07 | Merck & Co., Inc. | 1-(amino)indanes and (1,2-dihydro-3-amino)-benzofurans, benzothiophenes and indoles as edg receptor agonists |
| EP3889142B1 (en) | 2003-04-11 | 2022-06-15 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| JP2007528872A (ja) * | 2003-10-01 | 2007-10-18 | メルク エンド カムパニー インコーポレーテッド | Ｓ１ｐ受容体アゴニストとしての３，５−アリール置換、ヘテロアリール置換またはシクロアルキル置換された１，２，４−オキサジアゾール化合物 |
| CA2547198A1 (en) | 2003-12-17 | 2005-06-30 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists |
| US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| US20060173183A1 (en) | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| CA2600008A1 (en) | 2005-02-22 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| KR100667075B1 (ko) | 2005-07-22 | 2007-01-10 | 삼성에스디아이 주식회사 | 주사 구동부 및 이를 포함하는 유기 전계발광 표시장치 |
| AU2006278718B2 (en) † | 2005-08-03 | 2010-10-07 | Secura Bio Inc. | Use of HDAC inhibitors for the treatment of myeloma |
| EP1924546A1 (en) | 2005-09-14 | 2008-05-28 | Amgen, Inc | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| PE20070705A1 (es) * | 2005-11-25 | 2007-08-23 | Basf Ag | Compuestos de indanil - y tetrahidronaftil-amino-azolina para combatir pestes animales |
| EP1963509A4 (en) | 2005-12-21 | 2009-07-29 | Joseph Gabriele | CATECHOLAMINE-REGULATED PROTEIN |
| EP2007749A2 (en) | 2006-03-13 | 2008-12-31 | Pfizer Products Inc. | Tetralines antagonists of the h-3 receptor |
| US20080009534A1 (en) * | 2006-07-07 | 2008-01-10 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| KR20090051774A (ko) * | 2006-09-21 | 2009-05-22 | 액테리온 파마슈티칼 리미티드 | 페닐 유도체 및 면역조절제로서 이들의 용도 |
| CA2669104A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
| KR20090095648A (ko) | 2006-12-15 | 2009-09-09 | 아보트 러보러터리즈 | 신규한 옥사디아졸 화합물 |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| WO2008106204A1 (en) | 2007-02-28 | 2008-09-04 | Rib-X-Pharmaceuticals, Inc. | Macrolide compounds and methods of making and using the same |
| GB0725104D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| US20090298894A1 (en) | 2008-04-21 | 2009-12-03 | Asahi Kasei Pharma Corporation | Amino acid compounds |
| MY156381A (en) * | 2008-05-14 | 2016-02-15 | Scripps Research Inst | Novel modulators of sphingosine phosphate receptors |
| WO2009151259A1 (ko) * | 2008-06-13 | 2009-12-17 | 두원공과대학교 | 로터리 밸브를 구비한 왕복동 압축기 |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
| GB0911130D0 (en) | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
| RS57070B1 (sr) | 2009-11-13 | 2018-06-29 | Celgene Int Ii Sarl | Modulatori sfingozin 1 fosfatnog receptora i postupci asimetričnih sinteza |
| MY161854A (en) | 2009-11-13 | 2017-05-15 | Receptos Inc | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
| EA025672B1 (ru) | 2009-11-13 | 2017-01-30 | Рецептос Ллк | Селективные гетероциклические модуляторы рецептора сфингозин-1-фосфата |
| ES2758841T3 (es) | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
| CN106344576A (zh) | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
-
2010
- 2010-11-15 MY MYPI2012002084A patent/MY161854A/en unknown
- 2010-11-15 EP EP20215106.4A patent/EP3868377A1/en not_active Withdrawn
- 2010-11-15 KR KR1020127015292A patent/KR101721716B1/ko active Active
- 2010-11-15 EA EA201290323A patent/EA024801B1/ru not_active IP Right Cessation
- 2010-11-15 WO PCT/US2010/056760 patent/WO2011060392A1/en not_active Ceased
- 2010-11-15 PT PT108308800T patent/PT2498610T/pt unknown
- 2010-11-15 BR BR122018077504A patent/BR122018077504B8/pt active IP Right Grant
- 2010-11-15 CA CA2986521A patent/CA2986521C/en active Active
- 2010-11-15 LT LTEP18160667.4T patent/LT3406142T/lt unknown
- 2010-11-15 JP JP2012539065A patent/JP5650233B2/ja active Active
- 2010-11-15 DK DK18160667.4T patent/DK3406142T3/da active
- 2010-11-15 SI SI201032063T patent/SI3406142T1/sl unknown
- 2010-11-15 PT PT181606674T patent/PT3406142T/pt unknown
- 2010-11-15 SM SM20180288T patent/SMT201800288T1/it unknown
- 2010-11-15 CN CN201080061144.8A patent/CN102762100B/zh active Active
- 2010-11-15 NO NO10830880A patent/NO2498610T3/no unknown
- 2010-11-15 SI SI201031704T patent/SI2498610T2/sl unknown
- 2010-11-15 ES ES18160667T patent/ES2858337T3/es active Active
- 2010-11-15 PL PL18160667T patent/PL3406142T3/pl unknown
- 2010-11-15 KR KR1020167035297A patent/KR101752124B1/ko active Active
- 2010-11-15 HU HUE10830880A patent/HUE037535T2/hu unknown
- 2010-11-15 NZ NZ599915A patent/NZ599915A/en unknown
- 2010-11-15 PL PL10830880.0T patent/PL2498610T5/pl unknown
- 2010-11-15 RS RS20180647A patent/RS57253B2/sr unknown
- 2010-11-15 TR TR2018/07912T patent/TR201807912T4/tr unknown
- 2010-11-15 HU HUE18160667A patent/HUE054000T2/hu unknown
- 2010-11-15 US US12/946,819 patent/US8362048B2/en active Active
- 2010-11-15 PH PH1/2012/500939A patent/PH12012500939A1/en unknown
- 2010-11-15 CN CN201510295907.XA patent/CN105061350B/zh active Active
- 2010-11-15 SM SM20210169T patent/SMT202100169T1/it unknown
- 2010-11-15 EP EP10830880.0A patent/EP2498610B2/en active Active
- 2010-11-15 AU AU2010319983A patent/AU2010319983B2/en active Active
- 2010-11-15 RS RS20210360A patent/RS61829B1/sr unknown
- 2010-11-15 MX MX2012005560A patent/MX2012005560A/es active IP Right Grant
- 2010-11-15 SG SG10201407357PA patent/SG10201407357PA/en unknown
- 2010-11-15 ES ES10830880T patent/ES2673160T5/es active Active
- 2010-11-15 CA CA2780772A patent/CA2780772C/en active Active
- 2010-11-15 EP EP18160667.4A patent/EP3406142B8/en active Active
- 2010-11-15 LT LTEP10830880.0T patent/LT2498610T/lt unknown
- 2010-11-15 MY MYPI2016002092A patent/MY189750A/en unknown
- 2010-11-15 EA EA201690391A patent/EA035768B1/ru not_active IP Right Cessation
- 2010-11-15 BR BR112012011427A patent/BR112012011427B8/pt active IP Right Grant
- 2010-11-15 HR HRP20180874TT patent/HRP20180874T4/hr unknown
- 2010-11-15 DK DK10830880.0T patent/DK2498610T4/da active
-
2012
- 2012-05-09 IL IL219691A patent/IL219691B/en active IP Right Grant
-
2013
- 2013-01-14 US US13/740,661 patent/US20130231326A1/en not_active Abandoned
- 2013-11-14 JP JP2013235966A patent/JP5982705B2/ja active Active
-
2014
- 2014-11-12 JP JP2014229895A patent/JP2015038145A/ja active Pending
-
2015
- 2015-02-26 US US14/632,675 patent/US9388147B2/en active Active
- 2015-12-04 PH PH12015502708A patent/PH12015502708B1/en unknown
-
2017
- 2017-01-13 US US15/406,128 patent/US10239846B2/en active Active
-
2018
- 2018-06-12 CY CY20181100611T patent/CY1120338T1/el unknown
-
2019
- 2019-07-09 IL IL267956A patent/IL267956B/en active IP Right Grant
-
2020
- 2020-11-18 LU LU00184C patent/LUC00184I2/en unknown
- 2020-11-18 FR FR20C1059C patent/FR20C1059I2/fr active Active
- 2020-11-18 HU HUS2000045C patent/HUS2000045I1/hu unknown
- 2020-11-18 NO NO2020039C patent/NO2020039I1/no unknown
- 2020-11-18 LT LTPA2020533C patent/LTC2498610I2/lt unknown
- 2020-11-19 CY CY2020035C patent/CY2020035I2/el unknown
-
2021
- 2021-03-17 HR HRP20210446TT patent/HRP20210446T1/hr unknown
- 2021-03-22 CY CY20211100241T patent/CY1124121T1/el unknown
-
2024
- 2024-02-29 FI FIEP10830880.0T patent/FI2498610T4/fi active